Back to top
more

Agios Pharmaceuticals (AGIO)

(Real Time Quote from BATS)

$48.66 USD

48.66
44,981

+0.47 (0.98%)

Updated Jul 25, 2024 10:37 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss

by Zacks Equity Research

Agios posted wider-than-expected loss in the first quarter of 2018. Revenues came below expectations. Revenues also decreased year-over-year.

    Why Earnings Season Could Be Great for Agios (AGIO)

    by Zacks Equity Research

    Agios (AGIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?

      by Zacks Equity Research

      Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.

        Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline

        by Zacks Equity Research

        The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.

          The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

          by Zacks Equity Research

          The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

            Indrajit Bandyopadhyay headshot

            Pharma M&A Active This Week: 4 Potential Buyout Targets

            by Indrajit Bandyopadhyay

            Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

              Agios Pharmaceuticals Shares Rise on Buyout Speculation

              by Zacks Equity Research

              Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.

                FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

                by Zacks Equity Research

                FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

                  Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y

                  by Zacks Equity Research

                  Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.

                    Agios (AGIO) Q4 Loss Wider than Expected; Sales Miss

                    by Zacks Equity Research

                    Agios (AGIO) posted wider-than-expected loss in the fourth quarter of 2017. Revenues came below expectations. Revenues also decreased year-over-year.

                      Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?

                      by Zacks Equity Research

                      Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.

                        Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?

                        by Zacks Equity Research

                        Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.

                          What's in the Cards for Varian Medical (VAR) in Q1 Earnings?

                          by Zacks Equity Research

                          Varian Medical's (VAR) lackluster performance in Halcyon platform and disappointing financials are likely to dampen results in Q1.

                            Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

                            by Zacks Equity Research

                            Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.

                              Celgene Provides 2017 Preliminary Results & 2018 View

                              by Zacks Equity Research

                              Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.

                                Celgene to Acquire Impact Biomedicines to Boost Pipeline

                                by Zacks Equity Research

                                Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.

                                  Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?

                                  by Zacks Equity Research

                                  Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.

                                    Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.

                                    by Zacks Equity Research

                                    Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo

                                      by Arpita Dutt

                                      A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.

                                        Celgene (CELG) Down on Discouraging Data on Revlimid

                                        by Zacks Equity Research

                                        Celgene (CELG)'s stock declined as the phase III study, REVELANCE, for the label expansion of key drug Revlimid for untreated follicular lymphoma patients failed.

                                          Agios Posts New Data on Glioma Candidate from Dose Expansion

                                          by Zacks Equity Research

                                          Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.

                                            Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y

                                            by Zacks Equity Research

                                            Agios (AGIO) reports narrower-than-expected loss with revenues marginally beating estimates. The top line also improves year over year, thanks to reimbursement received from Celgene.

                                              Agios (AGIO) Q3 Loss Narrower than Expected, Sales Beat

                                              by Zacks Equity Research

                                              Agios posted narrower-than-expected loss in the third quarter of 2017. Revenues came above expectations. Revenues also increased year-over-year.

                                                Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?

                                                by Zacks Equity Research

                                                Agios' (AGIO) only marketed drug Idhifa that looks effective to cure patients with relapsed or refractory acute myeloid leukemia might drive the company's earnings in Q3.

                                                  Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View

                                                  by Zacks Equity Research

                                                  Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.